Related Experiment Videos
[Liver injury under tuberculostatic treatment]
Praxis
|April 9, 1997
Summary
Isoniazid, a tuberculosis drug, can cause significant liver injury. This case highlights the importance of monitoring patients for adverse effects during treatment.
Area of Science:
- Hepatology
- Pharmacology
- Infectious Diseases
Background:
- Tuberculosis (TB) treatment commonly involves a combination of drugs.
- Hepatotoxicity is a known risk associated with anti-TB medications.
Observation:
- A patient developed nausea, loss of appetite, and elevated aminotransferase levels eightfold above normal.
- These symptoms appeared two weeks after initiating treatment with isoniazid, rifampicin, and pyrazinamide.
Findings:
- Isoniazid was identified as the most probable cause of drug-induced liver injury (DILI).
- Rifampicin and pyrazinamide are less frequently implicated in hepatotoxicity during TB therapy.
Implications:
- This case underscores the need for vigilant monitoring of liver function in patients undergoing TB treatment.
- Comparing current guidelines for patient monitoring and clinical management of anti-TB drug-induced liver injury is crucial.